All tests have been performed on commercial pigs from high health farms with donation of swine genetic materials as part of the Consortium. For each trial one company was requested to provide 200 pigs at weaning from PRRSV negative (PRRSV-), Mycoplasma hyopneumoniae-, and swine influenza virus- farms, and if possible from porcine circovirus type 2 (PCV2) free farms. Pigs could be from vaccinated sows since maternal antibody prevents them from becoming infected with PCV2. The source populations were crossbred commercial pigs (Genus/PIC USA; Newsham Choice Genetics; Fast Genetics; Genetiporc, Inc.; Genesus Genetics) with complete parentage and pedigree records. Since SNP chips are used for genotyping there was a decreased need for extensive family structure. There was no preselection of sires for disease traits. Pigs (~200/trial) were transported to the biosecure Kansas State University (KSU) testing facility at weaning. All pig experiments were initiated after approval by KSU IACUC and IBC institutional committees. After arrival pigs were treated with broad spectrum antibiotics for 1 week, to prevent expression of other organisms.
Free full text: Click here